Tony Kalajian

Tony Kalajian

No más puestos en curso

Fortuna: 44 606 $ al 30/04/2024

54 años
Health Technology
Consumer Services
Commercial Services

Perfil

Tony Kalajian worked as a Senior Director-Finance at STAAR Surgical Co. from 2013 to 2016.
He then worked as the Chief Accounting Officer & Vice President at Lineage Cell Therapeutics, Inc. from 2016 to 2019.
Prior to that, he was a Senior Manager-Audit at PricewaterhouseCoopers LLP.
In 2019, he became the Chief Accounting Officer & Senior Vice President at OncoCyte Corp.
until 2020.
He also worked as the Chief Financial & Accounting Officer at Calidi Biotherapeutics, Inc. Mr. Kalajian received his undergraduate degree from The California State University and his MBA from USC Marshall School of Business.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
12/09/2023 278 790 ( 0.78% ) 44 606 $ 30/04/2024

Antiguos cargos conocidos de Tony Kalajian.

EmpresasCargoFin
CALIDI BIOTHERAPEUTICS, INC. Director Financiero/CFO 23/10/2023
ONCOCYTE CORPORATION Comptroller/Controller/Auditor 18/12/2020
LINEAGE CELL THERAPEUTICS, INC. Comptroller/Controller/Auditor 01/08/2019
STAAR SURGICAL COMPANY Director Financiero/CFO 01/04/2016
Corporate Officer/Principal -
Ver el detalle de la experiencia de Tony Kalajian.

Formación de Tony Kalajian.

The California State University Undergraduate Degree
USC Marshall School of Business Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Tony Kalajian.

Relaciones

39

Relaciones de 1er grado

7

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas4
ONCOCYTE CORPORATION

Health Technology

LINEAGE CELL THERAPEUTICS, INC.

Health Technology

STAAR SURGICAL COMPANY

Health Technology

CALIDI BIOTHERAPEUTICS, INC.

Health Technology

Empresas privadas1

Commercial Services

Ver las conexiones de la empresa
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA